Fundraising FoxAdicet Bio
NASDAQ: ACETMenlo Park, US · Founded 2014 · Delaware corporation · 7 known investors
Find your way into Adicet Bio
Sign up to see every warm intro you have to Adicet Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Adicet Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer. The company works on off-the-shelf immune cell therapies based on gamma delta 1 CAR T cell technology.
Founders & leadership
Adicet Bio was founded in 2014 by Aya Jakobovits.
AJ
Aya JakobovitsFounder
NH
Nathan HubbardChief Business Officer2015–2016Nathan Hubbard is an executive with over 20 years of healthcare experience, including business development, strategy, and operational leadership roles across multiple markets and geographies. He has expertise in oncology and hematology, with background in commercialization, M&A, and product launches across various stages of development.
Board
JS
CG
FG
Florent GrosBoard director
EC
Investors · 7
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75Mvia Carl Gordon · board
How we know: OrbiMed's portfolio page · the S-1 prospectus · board seat on SEC Form D · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Pontifax Venture Capitallisted by Pontifax Venture CapitalHerzeliya
How we know: Pontifax Venture Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
aMooninferredRa'ananavia Yair Schindel · board
How we know: board seat on SEC Form D · Not right? Tell us
Novartis Venture FundreportedBasel · $5M – $25M
How we know: funding news · Not right? Tell us
PureTech HealthreportedBoston
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$156.8M disclosed across 4 rounds · 2015–2019
▶$80MraisedOct 2019 · 18 investors · BiotechnologyRule 506(b)
▶$80MraisedOct 2019 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Erez ChimovitsDirector
- Francesco GaliniExecutive Officer
- Carrie KrehlikExecutive Officer
- Stewart AbbotExecutive Officer
- Carl GordonDirector
- Michal SilverbergDirector
- Donald SantelExecutive Officer, Director
- Yair SchindelDirector
- Asish XavierDirector
- Aya JakobovitsDirector
- Offering amount
- $80M
- Amount sold
- $80M
- Sales commissions
- $2.5M
- Placement agents
- Beech Hill Securities, Inc., Beech Hill Securities, Inc., Beech Hill Securities, Inc.
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$25.4MraisedOct 2018 · 5 investors · BiotechnologyRule 506(b)
▶$25.4MraisedOct 2018 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SilversteinDirector
- Aya JakobovitsDirector
- Donald SantelExecutive Officer, Director
- Brian HoganExecutive Officer
- Carl GordonDirector
- Carrie KrehlikExecutive Officer
- Anne AltmeyerExecutive Officer
- Florent GrosDirector
- Erez ChimovitsDirector
- Steward AbbotExecutive Officer
- Offering amount
- $43.3M
- Amount sold
- $25.4M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$11.3MraisedJan 2016 · 6 investors · BiotechnologyRule 506(b)
▶$11.3MraisedJan 2016 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nathan HubbardExecutive Officer
- Aya JakobovitsExecutive Officer, Director
- Jonathan SilversteinDirector
- Carl GordonDirector
- Florent GrosDirector
- Erez ChimovitsDirector
- Offering amount
- $13.9M
- Amount sold
- $11.3M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$407.9Mvaluation at IPOJan 2018 · $15.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 8
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
TipRanksFinancial analysis and stock research platform.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies working in the same space as Adicet Bio.
In the news
Frequently asked questions
- What does Adicet Bio do?
- Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer. The company works on off-the-shelf immune cell therapies based on gamma delta 1 CAR T cell technology.
- Who founded Adicet Bio?
- Adicet Bio was founded by Aya Jakobovits in 2014.
- Who are Adicet Bio's investors?
- Adicet Bio's investors include Foresite Capital, OrbiMed, Pontifax Venture Capital, Quan Capital, aMoon, Novartis Venture Fund, PureTech Health.
- How much funding has Adicet Bio raised?
- Adicet Bio has disclosed $156.8M raised across 4 rounds.
- Where is Adicet Bio headquartered?
- Adicet Bio is headquartered in Menlo Park, US.